Evidence map›Paper›PMID 41233512›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

[

Margret Schottelius, David Viertl, Tessa Buckle, Hélène Koch, Sebastian Martin, Alexandra Litvinenko, Marianne Patt, D M van Willigen, Fijs W B van Leeuwen, Hans-Jürgen Wester and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Nuclear medicine in the operating room: present and future.The British journal of radiology · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Margret SchotteliusTranslational Radiopharmaceutical Sciences, Department of Nuclear Medicine, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, 1011, Switzerland. margret.schottelius@chuv.ch.ORCID 0000-0002-1928-6913
David ViertlTranslational Radiopharmaceutical Sciences, Department of Nuclear Medicine, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, 1011, Switzerland.
Tessa BuckleInterventional Molecular Imaging Laboratory, Leiden University Medical Center, Leiden, 2333 ZA, The Netherlands.
Hélène KochTranslational Radiopharmaceutical Sciences, Department of Nuclear Medicine, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, 1011, Switzerland.
Sebastian MartinTranslational Radiopharmaceutical Sciences, Department of Nuclear Medicine, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, 1011, Switzerland.
Alexandra LitvinenkoTranslational Radiopharmaceutical Sciences, Department of Nuclear Medicine, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, 1011, Switzerland.
Marianne PattNuclear Medicine, University of Augsburg, 86156, Augsburg, Germany.
D M van WilligenInterventional Molecular Imaging Laboratory, Leiden University Medical Center, Leiden, 2333 ZA, The Netherlands.
Fijs W B van LeeuwenInterventional Molecular Imaging Laboratory, Leiden University Medical Center, Leiden, 2333 ZA, The Netherlands.
Hans-Jürgen WesterChair for Pharmaceutical Radiochemistry, Faculties of Chemistry and Medicine, Technische Universität München, 85748, Garching, Germany.
Dorothea WeckermannUrology, Medical Faculty, University of Augsburg, 86156, Augsburg, Germany.
Alessandro LiebichNuclear Medicine, University of Augsburg, 86156, Augsburg, Germany.
Alexander GäbleNuclear Medicine, University of Augsburg, 86156, Augsburg, Germany.
Nic G ReitsamPathology, Medical Faculty, University of Augsburg, 86156, Augsburg, Germany.
Bruno MärklPathology, Medical Faculty, University of Augsburg, 86156, Augsburg, Germany.
Johanna S EnkeNuclear Medicine, University of Augsburg, 86156, Augsburg, Germany.
Julia Brosch-LenzNuclear Medicine, University of Augsburg, 86156, Augsburg, Germany.
Constantin LapaNuclear Medicine, University of Augsburg, 86156, Augsburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo develop a dual-labeled PSMA-targeted tracer for radio- and fluorescence-guided surgery (RGS/FGS) with enhanced clinical utility due to optimized pharmacokinetics and tumor targeting.

methodsFour novel hybrid PSMA ligands with varying cyanine-based fluorophores were comprehensively characterized preclinically. On the basis of its excellent in vitro (logD, plasma protein binding, PSMA-affinity, internalization) and in vivo (stability, clearance kinetics, tumor uptake in LNCaP and PC3-PIp tumor-bearing mice) profile, [

resultsThe PSMA affinity (IC₅₀=38.4 ± 5.3 nM), hydrophilicity (logD =-2.94), and human plasma protein binding of [

conclusionsThe hybrid tracer [

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IIOrganotechnetium CompoundsProstatic NeoplasmsSurgery, Computer-AssistedAnimalsCell Line, TumorHumansMaleMiceRadiopharmaceuticalsSingle Photon Emission Computed Tomography Computed TomographyTissue DistributionAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIOrganotechnetium CompoundsRadiopharmaceuticalsFluorescence guided surgeryHybrid tracerProstate cancer (PCa)PSMARadioguided surgery

Identifiers

PMID41233512
PMCPMC13013135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.